Pre-formulation screens for BCS Class II API candidates in oral tablet and capsule programs begin with phase solubility analysis under Higuchi-Connors conditions. When a poorly soluble weak acid shows equilibrium solubility below 0.05 mg/mL in pH 1.2 0.1 N HCl and pH 6.8 phosphate buffer at 37°C ± 0.5°C, a 1:1 to 1:3 drug-to-methyl-β-cyclodextrin molar ratio is screened in 0–150 mM aqueous methyl-β-cyclodextrin. An AL-type phase solubility profile confirms linear solubility increase, while an AP-type profile indicates higher-order complexation requiring re-optimization of molar charge. The spray-dried complex is prepared by dissolving methyl-β-cyclodextrin in Purified Water USP at 40.0% w/w solids, adding the API under high-shear mixing at 6,000–10,000 rpm, and feeding the solution to a Büchi B-290 or Niro Mobile Minor spray dryer at inlet 120–140°C, outlet 60–75°C, and atomization pressure 3.0–4.5 bar. The resulting amorphous complex has bulk density 0.30–0.45 g/cm³; residual methanol is controlled below the ICH Q3C Class 2 limit of 3,000 ppm because the methyl ether substituent can arise from the cyclodextrin manufacturing route. Batch release includes headspace gas chromatography per USP <467>. The spray-dried intermediate must be stored below 40% RH; moisture uptake above 5.0% w/w accelerates drug recrystallization and reduces dissolution recovery. Tableting uses a Korsch XL 100 rotary press with compression force 8–18 kN and target hardness 60–100 N; disintegration is tested per USP <701> in 900 mL aqueous medium with a limit of ≤15 min. Capsule filling on a Zanasi 40E or MG2 compact machine requires Carr index ≤25% and Hausner ratio ≤1.35 to maintain powder flow. Terminal products are immediate-release tablets, hard gelatin capsules, and liquid-filled hard capsules when the spray-dried complex is suspended in medium-chain triglycerides.

What Limits Direct Compression Loading of Methylated β-Cyclodextrin in High-Dose Tablet Cores?

Direct compression trials on a Fette 2090i production press show that methyl-β-cyclodextrin complexed powders containing 30–40 wt% active ingredient exhibit acceptable tabletability only when the formulation includes 20–35 wt% microcrystalline cellulose PH102 and 1.5–2.5 wt% magnesium stearate lubricant. Above 45.0 wt% complex loading, capping occurs at main compression force above 14 kN due to high elastic recovery of the methylated cyclodextrin matrix; the process rectification is a short wet granulation pre-step using a binder solution prepared from 5.0 wt% methyl-β-cyclodextrin in Purified Water USP. Granulation in a high-shear Diosna P1-6 mixer at impeller 300 rpm, chopper 1,500 rpm, and 120–180 s, followed by fluid-bed drying to loss on drying 1.5–2.5% at inlet 60°C, restores compactibility and reduces ejection force below 3,500 N on an instrumented single-station press. For capsule direct-fill blends, flow function coefficient is measured by Schulze ring shear tester and must exceed 7.0 to prevent recurring friction-induced powder bridging in dosator nozzles. Blend segregation after vacuum transfer is controlled by sampling the transfer line; content uniformity assays at the beginning, middle, and end of the transfer must fall within 95.0–105.0% of target by USP <905>. Regulatory file build references USP <711> dissolution in 900 mL of 0.01 N HCl or phosphate buffer pH 6.8 at 50 rpm paddle, with sampling at 10, 15, 30, 45, and 60 min; an immediate-release specification of not less than 80% dissolved at 45 min is typical. Terminal product is a 250–500 mg tablet core with final hardness 70–110 N, or size 1–0 hard gelatin capsules containing loaded complex granules. Batch-to-batch variance in complexation stoichiometry is monitored by differential scanning calorimetry: absence of the drug melting endotherm is accepted as in-process proof of inclusion, while Fourier-transform infrared spectroscopy tracks the shift of the drug carbonyl stretching band by 5–15 cm⁻¹.For parenteral solution development, methyl-β-cyclodextrin is evaluated when a sterile-filterable drug concentration of at least 1.0 mg/mL is required but intrinsic aqueous solubility is below 0.1 mg/mL at formulation pH. Phase solubility screening in Water for Injection at 25°C ± 0.5°C uses methyl-β-cyclodextrin concentrations from 2.0% to 20.0% w/v; the apparent stability constant K1:1 derived from the phase solubility slope is included in the ICH Q2(R1) validated robustness protocol. Osmolality is adjusted with sodium chloride or mannitol to 280–320 mOsm/kg by USP <785>, and the solution is filtered through a 0.22 µm PVDF membrane at differential pressure 0.8–1.2 bar. Terminal sterilization by autoclaving at 121°C for 15 min can shift inclusion equilibrium for thermolabile APIs; therefore, sterilizing-grade filtration plus aseptic filling is selected when the complex degrades more than 1.5% during a pilot autoclave cycle. Because methylated β-cyclodextrins show concentration-dependent hemolytic activity on rabbit erythrocyte suspension, the formulation file includes an in vitro hemolysis assay and sets the maximum injectable vehicle concentration below 15.0% w/v unless intravenous toxicity studies justify a higher level. Endotoxin limits are calculated by the USP <85> K/M formula and documented in the batch release specification before sterile filtration. Sterility per USP <71> and particulate matter per USP <788> for small-volume injections are release tests. Terminal products include 5 mL and 20 mL single-dose vials or a lyophilized presentation when the drug complex is unstable in solution beyond 48 h at 2–8°C.

When Aqueous Solubility Drops Below 0.2 mg/mL, Freeze-Drying Cycle Design Recalculates Collapse Temperature

Drug molecules requiring injectable delivery but exhibiting aqueous solubility below 0.2 mg/mL across pH 3.0–7.4 are complexed with methyl-β-cyclodextrin in Water for Injection before lyophilization. The collapse temperature of the frozen complex is measured by freeze-drying microscopy, and methyl-β-cyclodextrin at 5–15% w/v shifts the collapse temperature of a 2.5% w/v sucrose-free formulation by altering the amorphous frozen-phase viscosity; primary drying shelf temperature is set 2–4°C below collapse temperature, commonly between −30°C and −15°C at chamber pressure 60–120 mTorr. A loading ratio of 1:2 drug-to-methyl-β-cyclodextrin protects the API from adsorption to stainless steel lyophilizer shelves and reduces free drug concentration at the ice-water interface, a relevant variable for protonation-sensitive peptides. Annealing at −15°C for 2–4 h is introduced when batch thermocouple data show greater than 2°C inter-vial collapse temperature variation, producing a uniform dry cake. Residual water is measured by coulometric Karl Fischer titration per USP <921> with release limit not more than 1.0% w/w; residual methanol from the methyl-β-cyclodextrin manufacturing route is controlled by headspace gas chromatography per USP <467> with a limit of 3,000 ppm. The lyophilized cake is reconstituted with Water for Injection to the original fill volume; reconstitution time under manual swirling is typically less than 90 s for a 20 mL vial, and subvisible particles are checked per USP <788>. Terminal product is a 20 mL single-dose vial containing sterile lyophilized powder equivalent to 5 mg/mL drug after reconstitution. When collapse temperature shifts are not predictable from binary aqueous data, published data for this specific configuration is limited, and freeze-drying microscopy remains the only reliable method.

Control point	Application segment	Standard or reference	Typical acceptance window
Residual methanol	Oral / injectable / lyophilized	USP <467>, ICH Q3C Class 2	≤3,000 ppm
Dissolution	Immediate-release tablet / capsule	USP <711>	≥80% at 45 min
Osmolality	Injectable solution	USP <785>	280–320 mOsm/kg
Sterility	Injectable / lyophilized	USP <71>	No growth at 14 days
Bacterial endotoxins	Injectable / lyophilized	USP <85>	K/M formula; batch limit per dose
Residual moisture	Lyophilized cake	USP <921>	≤1.0% w/w
Particulate matter	Small-volume injection	USP <788>	SVIP limits
Tablet friability	Orally disintegrating tablet	USP <1216>	≤1.0%
Uniformity of dosage units	Granule suspension	USP <905>	95.0–105.0%

Oral disintegrating tablet development uses methyl-β-cyclodextrin for two simultaneous functions: stabilization of a moisture-sensitive API during direct compression and bitterness suppression through competitive inclusion of hydrophobic functional groups. The preformed complex is produced by lyophilization of a 1:1.5 drug-to-cyclodextrin solution in Purified Water USP for 36–48 h at shelf temperature −40°C and chamber pressure 80–100 mTorr; the resulting lyophile is milled through a 500 µm sieve and blended with mannitol, crospovidone, and microcrystalline cellulose. Because methyl-β-cyclodextrin is hygroscopic, exposure time in a 30–40% RH production suite is limited to less than 4 h before compression; out-of-limit moisture sorption above 3.0% w/w leads to premature softening of the ODT. Compression on a rotary tablet press with precompression force 4–6 kN and main compression force 8–12 kN yields 200 mg tablets with hardness 30–50 N, friability less than 1.0% per USP <1216>, and disintegration time below 30 s in 5 mL simulated saliva at 37°C. The tablets are packaged in cold-form aluminium foil blisters with molecular sieve desiccant when accelerated stability at 40°C/75% RH shows hardness loss beyond 10% in open dish tests. Release includes USP <711> dissolution in 0.1 N HCl and pH 4.5 acetate buffer; the terminal product is an orally disintegrating tablet for geriatric or paediatric dosing where the unit dose contains no more than 30 mg drug.

Granule Coating and Taste Masking in Paediatric Oral Suspension Formulations

For bitter APIs with logP above 2.5, methyl-β-cyclodextrin is applied as a wet granulation binder and molecular masker before barrier coating. The granulation fluid is a 10.0% w/w aqueous methyl-β-cyclodextrin solution in which the API is pre-solubilized at a molar ratio of 1:1.8; spraying onto a lactose-starch blend in a Glatt GPCG 3.1 fluid bed granulator at inlet temperature 55–60°C, spray rate 8–12 g/min, atomization pressure 1.5–2.0 bar, and product temperature 30–34°C results in granules with particle size D50 180–250 µm and residual moisture below 2.0% w/w. The complexed granules are subsequently coated with an aqueous ethylcellulose dispersion containing 20% solids and triethyl citrate as plasticizer to achieve 12–15% weight gain; coating is performed in the same fluid bed with Wurster insert at inlet 45–50°C and product temperature 28–32°C. The barrier coat releases drug in the stomach via pore diffusion; dissolution testing by USP <711> uses 900 mL pH 1.2 medium at 75 rpm paddle, with sampling at 5, 10, 20, 30, 45, 60, 90, and 120 min. Granules are mixed with xanthan gum, sucrose, sodium benzoate, and citric acid after terminal water correction. The terminal product is a multi-particulate powder for oral suspension in a 100 mL amber glass bottle; when reconstituted with 45 mL Purified Water, it yields a suspension of pH 4.5–5.5, viscosity 150–350 mPa·s, and dose uniformity of 95.0–105.0% per USP <905>. Inclusion complex stability is verified by differential scanning calorimetry and solubility recovery after 24 months at 25°C/60% RH.